Tirzepatide to Slow Biological Aging
NCT07220473 on ClinicalTrials.gov · last registry update 2026-03-24
Recruiting now, toward 90 participants. Due to report November 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in DNA Methylation-Based Biological Age. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- The University of Texas Medical Branch, Galveston
- Sponsor type
- Other
- Enrollment
- 90
- Started
- 2026-02-27
- Primary completion
- 2027-11 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in DNA Methylation-Based Biological Age
Conditions studied
Aging · LONGEVITY 1
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.